Literature DB >> 22932801

Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia.

Charles Gawad1, Francois Pepin, Victoria E H Carlton, Mark Klinger, Aaron C Logan, David B Miklos, Malek Faham, Gary Dahl, Norman Lacayo.   

Abstract

The ability to distinguish clonal B-cell populations based on the sequence of their rearranged immunoglobulin heavy chain (IgH) locus is an important tool for diagnosing B-cell neoplasms and monitoring treatment response. Leukemic precursor B cells may continue to undergo recombination of the IgH gene after malignant transformation; however, the magnitude of evolution at the IgH locus is currently unknown. We used next-generation sequencing to characterize the repertoire of IgH sequences in diagnostic samples of 51 children with B precursor acute lymphoblastic leukemia (B-ALL). We identified clonal IgH rearrangements in 43 of 51 (84%) cases and found that the number of evolved IgH sequences per patient ranged dramatically from 0 to 4024. We demonstrate that the evolved IgH sequences are not the result of amplification artifacts and are unique to leukemic precursor B cells. In addition, the evolution often follows an allelic exclusion pattern, where only 1 of 2 rearranged IgH loci exhibit ongoing recombination. Thus, precursor B-cell leukemias maintain evolution at the IgH locus at levels that were previously underappreciated. This finding sheds light on the mechanisms associated with leukemic clonal evolution and may fundamentally change approaches for monitoring minimal residual disease burden.

Entities:  

Mesh:

Year:  2012        PMID: 22932801      PMCID: PMC3507147          DOI: 10.1182/blood-2012-05-429811

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  A stable RAG1-RAG2-DNA complex that is active in V(D)J cleavage.

Authors:  K Hiom; M Gellert
Journal:  Cell       Date:  1997-01-10       Impact factor: 41.582

2.  Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy.

Authors:  V de Haas; O J Verhagen; A E von dem Borne; W Kroes; H van den Berg; C E van der Schoot
Journal:  Leukemia       Date:  2001-01       Impact factor: 11.528

Review 3.  Childhood acute lymphoblastic leukaemia--current status and future perspectives.

Authors:  C H Pui; D Campana; W E Evans
Journal:  Lancet Oncol       Date:  2001-10       Impact factor: 41.316

4.  Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease.

Authors:  Tomasz Szczepański; Marja J Willemse; Bas Brinkhof; Elisabeth R van Wering; Mirjam van der Burg; Jacques J M van Dongen
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

5.  Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia.

Authors:  G M Marshall; E Kwan; M Haber; M J Brisco; P J Sykes; A A Morley; I Toogood; K Waters; G Tauro; H Ekert
Journal:  Leukemia       Date:  1995-11       Impact factor: 11.528

6.  Distinct ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia.

Authors:  E J Steenbergen; O J Verhagen; E F van Leeuwen; A E von dem Borne; C E van der Schoot
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

7.  Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis.

Authors:  A Beishuizen; M A Verhoeven; E R van Wering; K Hählen; H Hooijkaas; J J van Dongen
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

8.  Clonal evolution in B-lineage acute lymphoblastic leukemia by contemporaneous VH-VH gene replacements and VH-DJH gene rearrangements.

Authors:  Y Choi; S J Greenberg; T L Du; P M Ward; P M Overturf; M L Brecher; M Ballow
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

9.  Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone.

Authors:  Marianne Konrad; Markus Metzler; Simon Panzer; Iris Ostreicher; Martina Peham; Reinald Repp; Oskar A Haas; Helmut Gadner; E Renate Panzer-Grumayer
Journal:  Blood       Date:  2002-12-27       Impact factor: 22.113

10.  Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification.

Authors:  Carmela Gurrieri; Peter McGuire; Hong Zan; Xiao-Jie Yan; Andrea Cerutti; Emilia Albesiano; Steven L Allen; Vincent Vinciguerra; Kanti R Rai; Manlio Ferrarini; Paolo Casali; Nicholas Chiorazzi
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

View more
  53 in total

Review 1.  Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.

Authors:  Nicholas J Short; Elias Jabbour; Maher Albitar; Marcos de Lima; Lia Gore; Jeffrey Jorgensen; Aaron C Logan; Jae Park; Farhad Ravandi; Bijal Shah; Jerald Radich; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2018-11-26       Impact factor: 10.047

2.  NF-κB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity.

Authors:  Katarina Ochodnicka-Mackovicova; Mahnoush Bahjat; Timon A Bloedjes; Chiel Maas; Alexander M de Bruin; Richard J Bende; Carel J M van Noesel; Jeroen E J Guikema
Journal:  Blood       Date:  2015-07-07       Impact factor: 22.113

3.  Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.

Authors:  Aaron C Logan; Nikita Vashi; Malek Faham; Victoria Carlton; Katherine Kong; Ismael Buño; Jianbiao Zheng; Martin Moorhead; Mark Klinger; Bing Zhang; Amna Waqar; James L Zehnder; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-24       Impact factor: 5.742

Review 4.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

5.  High-throughput sequencing of B- and T-lymphocyte antigen receptors in hematology.

Authors:  Edus H Warren; Frederick A Matsen; Jeffrey Chou
Journal:  Blood       Date:  2013-05-08       Impact factor: 22.113

6.  Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.

Authors:  Olga Sala Torra; Megan Othus; David W Williamson; Brent Wood; Ilan Kirsch; Harlan Robins; Lan Beppu; Margaret R O'Donnell; Stephen J Forman; Frederick R Appelbaum; Jerald P Radich
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-03       Impact factor: 5.742

7.  Acute lymphoblastic leukemia clonal distribution between bone marrow and peripheral blood.

Authors:  Carol Fries; Diana G Adlowitz; Janice M Spence; John P Spence; Philip J Rock; W Richard Burack
Journal:  Pediatr Blood Cancer       Date:  2020-04-11       Impact factor: 3.167

8.  Evaluation diagnostic usefulness of immunoglobulin light chains (Igκ, Igλ) and incomplete IGH D-J clonal gene rearrangements in patients with B-cell non-Hodgkin lymphomas using BIOMED-2 protocol.

Authors:  S Ghorbian; I Jahanzad; G R Javadi; E Sakhinia
Journal:  Clin Transl Oncol       Date:  2014-05-27       Impact factor: 3.405

9.  High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis.

Authors:  Katharine A Lombardo; David G Coffey; Alicia J Morales; Christopher S Carlson; Andrea M H Towlerton; Sarah E Gerdts; Francis K Nkrumah; Janet Neequaye; Robert J Biggar; Jackson Orem; Corey Casper; Sam M Mbulaiteye; Kishor G Bhatia; Edus H Warren
Journal:  Blood Adv       Date:  2017-03-21

10.  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Malek Faham; Jianbiao Zheng; Martin Moorhead; Victoria E H Carlton; Patricia Stow; Elaine Coustan-Smith; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.